SenderraRx, an independent specialty pharmacy, announced on Thursday that it has earned reaccreditation in Specialty Pharmacy from the Accreditation Commission for Health Care (ACHC), including a Distinction in Oncology.
The Oncology Distinction recognises Senderra's oncology-focused clinical oversight, medication management, patient education, adherence support, and care coordination for patients navigating complex cancer therapies.
The ACHC reaccreditation adds to Senderra's existing URAC accreditations in Specialty Pharmacy and Mail Service Pharmacy under URAC's version 6.0 standards. Collectively, these accreditations show that Senderra's pharmacy operations, medication distribution, patient management, and service practices have been independently evaluated against current industry standards.
Foresee gains NMPA approval for CAMCEVI 42 mg in China
ABL Texcell Diagnostics acquires IntegraGen assets to expand into precision oncology
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
Alpheus Medical starts new clinical trial of PoMA therapy in butterfly glioblastoma
Sophos IRB and ALCMI partner to support lung cancer research
Northwest Biotherapeutics and NHSBT collaborate to support production of DCVax-L
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
Voyager signs cancer research mission management contract
AstraZeneca completes USD2bn equity investment in Summit Therapeutics
GE HealthCare to acquire SOFIE Biosciences for USD945m
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK